Daewoong to launch oxybutynin gel in Korea

Daewoong Pharmaceutical announced Wednesday that it signed an exclusive licensing agreement with the U.S. based Antares Pharma to distribute Antares’s topical oxybutynin gel 3% product inn Korea.

Last December, The U.S. Food and Drug Administration (FDA) approved the oxybutynin product for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and freq...